RAPP
Rapport Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$40.45
−3.58%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.21
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$1.19
- EPS estimate
- -$1.12
- Revenue actual
- —
- Revenue estimate
- $2.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +4.0%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $64
- PT range
- $52 – $75
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$1.12 | -$1.19 | Miss -6.25% | — |
| May 7, 2026 | -$0.56 | -$0.42 | Beat 25.00% | $20.0M |
| Mar 10, 2026 | -$0.65 | -$0.72 | Miss -10.57% | — |
| Nov 6, 2025 | -$0.77 | -$0.71 | Beat 7.79% | — |
| Aug 7, 2025 | -$0.87 | -$0.75 | Beat 13.79% | — |
| May 8, 2025 | -$0.77 | -$0.68 | Beat 11.69% | — |
| Mar 11, 2025 | -$0.62 | -$0.57 | Beat 8.06% | — |
| Nov 7, 2024 | -$0.57 | -$0.50 | Beat 12.28% | — |
| Aug 8, 2024 | -$0.68 | -$1.70 | Miss -150.00% | — |
| Mar 30, 2024 | — | -$0.12 | — | — |
| Sep 30, 2023 | — | -$0.05 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026